1350473-57-2

Upstream product

• 100-39-0 benzyl bromide 
• 1123-40-6 3,3-dimethyl glutarimide 
• 106754-11-4 1-benzyl-4,4-dimethylpiperidine-2,6-dione 

Downstream Products

• 1350473-39-0 1-benzyl-4,4-dimethylpiperidin-3-amine 
• 1350473-40-3 N-(1-benzyl-4,4-dimethylpiperidin-3-yl)-2-cyclopropyl-5-((2-(trimethylsilyl)ethoxy)methyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide 

Relevant academic research and scientific papers

INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

PYRROLOPYRAZINE DERIVATIVES AS SYK AND JAK INHIBITORS

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula (I), wherein the variables Q and R1 and R2 are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.